6ER-002 Assessement of efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (i-pcsk9) for hypercholesterolaemia with or without statins

BACKGROUND: Proprotein inhibitors convertase subtilisin/kexin9 (i-PCSK9) are new drugs for hypercholesterolaemia used in monotherapy or in combination with statins, which have numerous interactions. It may be useful to study the efficacy of I-PCSK9 as a single therapy. PURPOSE: To compare the effica...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Hosp Pharm
Egile Nagusiak: Aguilar, E, Dani, L, Carmona, I Moya, Estaun, C, Ovies, JM Fernández
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2018
Gaiak:
Section 6: Education and research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535384/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.495
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak